Delpacibart Etedesiran - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Modal Labs has secured $750 million in Series D funding at a $15.75 billion valuation, marking a nearly 239% valuation surge in five months as demand for AI inference, GPU cloud infrastructure and autonomous coding agents accelerates, pushing the company's annualized run rate beyond $1 billion. Representative image.

Modal valuation jumps 239% as AI infrastructure demand drives $750m Series D

Salad and Go is coming back after bankruptcy, but competitors bought most of its old drive-thru network

Patient volumes rose 10% at Montrose Regional Health, so why are 77 positions disappearing?

Royal Mail wants 2,500 fewer support roles. Can it afford a frontline retention problem too?

Read More

Pharma Industry News

Avidity Biosciences’ del-desiran granted orphan drug designation in Japan for myotonic dystrophy type 1

Find out how Avidity Biosciences' del-desiran could transform treatment for myotonic dystrophy type 1 after securing Japan's first Orphan Drug nod for DM1.

byPallavi Madhiraju

April 9, 2025

web analytics